Randomized Trialhigh evidence
Naltrexone Is Superior to Placebo for Abstinence and Craving Reduction in Alcohol-Associated Cirrhosis: NAL-CI Trial.
Liver international : official journal of the International Association for the Study of the Liver·September 1, 2026·PMID 42615276
Why it mattersAlcohol use disorder in cirrhosis carries high morbidity and mortality, yet no pharmacotherapy is approved. This trial provides evidence that naltrexone is safe and effective in this population, offering a potential treatment option where none existed.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled